<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03716622</url>
  </required_header>
  <id_info>
    <org_study_id>2018SDU-QILU-G112</org_study_id>
    <nct_id>NCT03716622</nct_id>
  </id_info>
  <brief_title>A Comparison of Clarithromycin-based and Furazolidone-based Bismuth-containing Regimens for H. Pylori Eradication</brief_title>
  <official_title>A Comparison of Clarithromycin-based and Furazolidone-based Bismuth-containing Regimens for H. Pylori Eradication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We aim to assess and compare the effectiveness of clarithromycin- and furazolidone-based
      regimens as primary therapies in eradicating H. pylori.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Helicobacter pylori plays a pivotal role in many diseases such as peptic ulcer disease and
      MALT lymphomas. And the prevalence of H. pylori is increasing in some parts of the world.

      However, the eradication becomes increasingly difficult due to the growing antibiotic
      resistance. Bismuth-containing quadruple regimens are now recommended to serve as first-line
      therapies. Bismuth-clarithromycin-containing and bismuth-furazolidone-containing quadruple
      regimens are both in the list of the first regimens. And recent antimicrobial susceptibility
      tests showed us that the clarithromycin was increasingly resisted while furazolidone remained
      hardly resisted. The comparison between the effects of bismuth-clarithromycin-containing and
      bismuth-furazolidone-containing quadruple regimens is not so clear.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 31, 2018</start_date>
  <completion_date type="Actual">August 31, 2019</completion_date>
  <primary_completion_date type="Actual">August 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the eradication rate of the two groups</measure>
    <time_frame>26 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">350</enrollment>
  <condition>Helicobacter Pylori</condition>
  <arm_group>
    <arm_group_label>bismuth-clarithromycin-containing group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in bismuth-clarithromycin-containing group will receive lansoprazole (Takepron) 30mg po bid, amoxicillin 1000mg po bid, bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and clarithromycin (Klacid) 500mg po bid for 14d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bismuth-furazolidone-containing quadruple group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients in bismuth-furazolidone-containing quadruple group will receive lansoprazole (Takepron) 30mg po bid, amoxicillin 1000mg po bid, bismuth subcitrate (Colloidal Bismuth Pectin) 240mg po bid, and furazolidone (Liteling) 100mg po bid for 14d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furazolidone</intervention_name>
    <description>bismuth-furazolidone-containing quadruple regimens</description>
    <arm_group_label>bismuth-furazolidone-containing quadruple group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>bismuth-clarithromycin-containing quadruple regimens</description>
    <arm_group_label>bismuth-clarithromycin-containing group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients, aged between 18 and 75years old, with positive H. pylori infection that was
             not eradicated by previous therapies are included. The H. pylori infection is
             confirmed by the positive rapid urease test or 13C-breath test.

        Exclusion Criteria:

          -  Patients with significant underlying disease including liver, cardiac, pulmonary, and
             renal diseases, neoplasia, coagulopathy and genetic diseases, history of gastric
             surgery, pregnancy, breast-feeding, active gastrointestinal bleeding, the use of PPI,
             NSAID or antibiotics during the 4 weeks prior to enrolment, and previous history of
             allergic reactions to any of the medications used in this protocol. Patients
             previously treated with H. pylori eradication regimens or those unwilling to
             participate in the study were also excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiuli Zuo, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qilu Hospital of Shandong University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Qilu hosipital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>257000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 21, 2018</study_first_submitted>
  <study_first_submitted_qc>October 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2018</study_first_posted>
  <last_update_submitted>June 20, 2020</last_update_submitted>
  <last_update_submitted_qc>June 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Xiuli Zuo</investigator_full_name>
    <investigator_title>director of Qilu Hospital gastroenterology department</investigator_title>
  </responsible_party>
  <keyword>Helicobacter Pylori</keyword>
  <keyword>furazolidone</keyword>
  <keyword>clarithromycin</keyword>
  <keyword>bismuth-containing quadruple regimen</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Furazolidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

